Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||H3B-6527 + Palbociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|H3B-6527||H3B6527||FGFR4 Inhibitor 8||H3B-6527 selectively inhibits FGFR4, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth inhibition (PMID: 29247039, PMID: 31770593).|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 11||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|